Hepatology: Hepatocellular carcinoma in a young man secondary to androgenic anabolic steroid abuse

Kesler, Thomas J.; Rs, Sandhu; Krishnamoorthy, Saravanan

doi:10.1111/jgh.12809

Cited by 13 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Long-term consumption of injectables clubbed with oral preparations and polypharmacy predisposes one to development of hepatocellular adenoma (HA), HUMP and HCC. 2,3,6,7 The cholestatic injury and steatohepatitis noted in the first and third case, generally presents after short duration of AAS consumption and clinically manifest with SALF, with a prolonged plateau in clinical symptoms and biochemistry parameters; however, medical management and supportive therapies such as TPE accelerates hepatic regeneration, as observed in our cases. The period of medical management can take as long as 3 months, as seen in our patients, and this can avoid liver transplantation.…”

Section: Anabolic Androgenic Steroid Induced Hepatotoxicity Patil Et Alsupporting

confidence: 62%

Versatility of Anabolic Androgenic Steroid–Induced Hepatotoxicity

Patil

Jothimani

Harika

et al. 2022

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Section: Anabolic Androgenic Steroid Induced Hepatotoxicity Patil Et Alsupporting

confidence: 62%

Versatility of Anabolic Androgenic Steroid–Induced Hepatotoxicity

Patil

Jothimani

Harika

et al. 2022

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

“…Re-admitted with pruritusMedical therapy [129]SpainCRHepatic rupture, liver failure. Hematoma of the liverSurgery [130]USACRAcute, nonobstructive, intrahepatic cholestatic hepatitisMedical therapy; advice to avoid other medications [131]USACRSevere jaundice, bile acid nephropathyMedical therapy, blood transfusion, AAS discontinued [132]SpainCSSevere cholestasis, hepatotoxicityMedical therapy followed by MARS therapy [133]BrazilCRGiant hepatic adenomaSurgery [134]GermanyCRHepatocellular carcinomaSurgeryKidney ( n = 6) [135]USACRInitial diagnosis of hepatic adenomatosis (2004). On third admission, diagnosed with chronic kidney disease and coronary artery disease (2013)Advice given to discontinue AAS initially.…”

Section: Resultsmentioning

confidence: 99%

Treatments for people who use anabolic androgenic steroids: a scoping review

et al. 2019

View full text Add to dashboard Cite

Background: A growing body of evidence suggests that anabolic androgenic steroids (AAS) are used globally by a diverse population with varying motivations. Evidence has increased greatly in recent years to support understanding of this form of substance use and the associated health harms, but there remains little evidence regarding interventions to support cessation and treat the consequences of use. In this scoping review, we identify and describe what is known about interventions that aim to support and achieve cessation of AAS, and treat and prevent associated health problems.Methods: A comprehensive search strategy was developed in four bibliographic databases, supported by an iterative citation searching process to identify eligible studies. Studies of any psychological or medical treatment interventions delivered in response to non-prescribed use of AAS or an associated harm in any setting were eligible. Results: In total, 109 eligible studies were identified, which included case reports representing a diverse range of disciplines and sources. Studies predominantly focussed on treatments for harms associated with AAS use, with scant evidence on interventions to support cessation of AAS use or responding to dependence. The types of conditions requiring treatment included psychiatric, neuroendocrine, hepatic, kidney, cardiovascular, musculoskeletal and infectious. There was limited evidence of engagement with users or delivery of psychosocial interventions as part of treatment for any condition, and of harm reduction interventions initiated alongside, or following, treatment. Findings were limited throughout by the case report study designs and limited information was provided.Conclusion: This scoping review indicates that while a range of case reports describe treatments provided to AAS users, there is scarce evidence on treating dependence, managing withdrawal, or initiating behaviour change in users in any settings. Evidence is urgently required to support the development of effective services for users and of evidence-based guidance and interventions to respond to users in a range of healthcare settings. More consistent reporting in articles of whether engagement or assessment relating to AAS was initiated, and publication within broader health-or drug-related journals, will support development of the evidence base.

show abstract

“…The administration of an avocado oil-based diet was also beneficial in this study, as it significantly reduced indicators of hepatic damage in the IAOG animals. The use of anabolic agents increases the risk of developing hepatic neoplasms with a serious prognosis for the user (36,38). The consumption of avocado oil, as observed in its effects, can protect the liver and even be an ally in the therapy against hepatic neoplasms and other chemically induced cancers (39).…”

Section: Discussionmentioning

confidence: 99%